Viatris (VTRS) Capital Expenditures (2020 - 2026)
Viatris (VTRS) posted Capital Expenditures of $52.8 million for Q2 2026, up 32.33% on a QoQ basis from $39.9 million in Q1 2026, and little changed year-over-year from $52.9 million in Q2 2025.
Analysis
Viatris (VTRS) Capital Expenditures (2020 - 2026) Analysis & Trends
Viatris has reported Capital Expenditures for 7 years, with the latest figure at $52.8 million in Q2 2026.
- On a quarterly basis, Capital Expenditures changed 0.19% year-over-year to $52.8 million in Q2 2026; TTM through Jun 2026 was $376.0 million, a 20.17% increase from a year earlier, with the FY2025 full-year figure at $378.8 million, up 16.2% from the prior year.
- Capital Expenditures was $52.8 million for Q2 2026 at Viatris, up from $39.9 million in the prior quarter.
- The five-year high for Capital Expenditures was $196.5 million in Q4 2025, with the low at $39.9 million in Q1 2026.
- Average Capital Expenditures over 5 years is $87.8 million, with a median of $72.4 million recorded in 2023.
- The sharpest annual moves came in 2023 and 2025: Capital Expenditures decreased 25.89% in 2023, then soared 39.96% in 2025.
- Over 5 years, Capital Expenditures stood at $153.7 million in 2022, then climbed by 7.68% to $165.5 million in 2023, then retreated by 15.17% to $140.4 million in 2024, then soared by 39.96% to $196.5 million in 2025, then plunged by 73.13% to $52.8 million in 2026.
- The last three Capital Expenditures figures came in at $52.8 million (Q2 2026), $39.9 million (Q1 2026), and $196.5 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.84 Bn | 39.19 Bn | 2.15 Bn | 104.00 Mn |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn | 52.80 Mn |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.74 Bn | 396.53 Mn | -36.19 Mn |
| 4 | Amneal Pharmaceuticals | 5.51 Bn | 5.38 Bn | 334.51 Mn | 30.70 Mn |
| 5 | Bausch Health Companies | 2.30 Bn | 464.50 Mn | 2.10 Bn | 77.00 Mn |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | -27.87 Mn |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 3.05 Mn |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 714.13 Mn | 93.47 Mn | 8.59 Mn |
| 9 | Fennec Pharmaceuticals | 402.10 Mn | 360.85 Mn | 17.15 Mn | - |
| 10 | RedHill Biopharma | 178.35 Mn | 178.35 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 52.80 Mn |
| Mar 31, 2026 | 39.90 Mn |
| Dec 31, 2025 | 196.50 Mn |
| Sep 30, 2025 | 86.80 Mn |
| Jun 30, 2025 | 52.90 Mn |
| Mar 31, 2025 | 42.60 Mn |
| Dec 31, 2024 | 140.40 Mn |
| Sep 30, 2024 | 77.00 Mn |
| Jun 30, 2024 | 58.80 Mn |
| Mar 31, 2024 | 49.80 Mn |
| Dec 31, 2023 | 165.50 Mn |
| Sep 30, 2023 | 95.90 Mn |
| Jun 30, 2023 | 67.80 Mn |
| Mar 31, 2023 | 47.80 Mn |
| Dec 31, 2022 | 153.70 Mn |
| Sep 30, 2022 | 103.90 Mn |
| Jun 30, 2022 | 83.90 Mn |
| Mar 31, 2022 | 64.50 Mn |
| Dec 31, 2021 | 197.40 Mn |
| Sep 30, 2021 | 121.00 Mn |